Interferon signatures in immune disorders and disease
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
The interferon (IFN) family and the type‐I IFNs specifically have an important and well‐characterized role in antiviral defence, immune modulation and cell‐cycle control and are regularly applied in the clinical context. Advances in high‐content technologies have facilitated an enhanced understanding of the global IFN response capable of being induced. Recent application of these technologies is improving our understanding of the specificity and subtleties associated with this response. This review considers our current understanding of the temporal gene profile induced through IFN stimulation across a diversity of disease conditions including autoimmune diseases, bacterial and viral infections. Understanding these signatures, the disease‐specific differences and the biological effects induced has the potential to facilitate IFN‐driven therapeutic development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis
Berry, M. P. R., Graham, C. M., McNab, F. W., Xu, Z., Bloch, S. A. A., Oni, T., Wilkinson, K. A., Banchereau, R., Skinner, J., Wilkinson, R. J., et al. (2010) · Nature · doi:10.1038/nature09247 · Cited by 1,898
Robertson, G., Hirst, M., Bainbridge, M., Bilenky, M., Zhao, Y., Zeng, T., Euskirchen, G., Bernier, B., Varhol, R., Delaney, A., et al. (2007) · Nature Methods · doi:10.1038/nmeth1068 · Cited by 1,454
Evolutionary genetic dissection of human interferons
Manry, J., Laval, G., Patin, E., Fornarino, S., Itan, Y., Fumagalli, M., Sironi, M., Tichit, M., Bouchier, C., Casanova, J.-L., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20111680 · Cited by 176
Abnormal T cell signal transduction in systemic lupus erythematosus
Kammer, G. M., Perl, A., Richardson, B. C., & Tsokos, G. C. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10192 · Cited by 139
Meraro, D., Gleit-Kielmanowicz, M., Hauser, H., & Levi, B.-Z. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.12.6224 · Cited by 105
Cited by
Regulation of type I interferon responses
Ivashkiv, L. B., & Donlin, L. T. (2014) · Nature Reviews Immunology · doi:10.1038/nri3581 · Cited by 3,297
Parsing the interferon transcriptional network and its disease associations
Mostafavi, S., Yoshida, H., Moodley, D., LeBoité, H., Rothamel, K., Raj, T., Ye, C. J., Chevrier, N., Zhang, S.-Y., Feng, T., et al. (2016) · Cell · doi:10.1016/j.cell.2015.12.032 · Cited by 337
“In addition, the interferon transcriptional signature is found elevated in blood cells in many diseases (Theofilopoulos et al., 2005; Forster, 2012), including bacterial or parasitic infections as might be expected (Berry et al., 2010) but also a range of auto-inflammatory disease like Systemic…”
The interferon signature in autoimmune diseases
Rönnblom, L., & Eloranta, M.-L. (2013) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e32835c7e32 · Cited by 294
Dinaciclib induces immunogenic cell death and enhances anti-PD1-mediated tumor suppression
Hossain, D. M. S., Javaid, S., Cai, M., Zhang, C., Sawant, A., Hinton, M., Sathe, M., Grein, J., Blumenschein, W., Pinheiro, E. M., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci94586 · Cited by 216
Type I Interferon Responses Drive Intrahepatic T Cells to Promote Metabolic Syndrome
Ghazarian, M., Revelo, X. S., Nøhr, M. K., Luck, H., Zeng, K., Lei, H., Tsai, S., Schroer, S. A., Park, Y. J., Chng, M. H. Y., et al. (2017) · Science Immunology · doi:10.1126/sciimmunol.aai7616 · Cited by 190
Metadata
- Authors
- Forster, S.
- Venue
- Immunology & Cell Biology
- Publisher
- Wiley
- Published
- 2012-04-10
- Volume
- 90
- Issue
- 5
- Pages
- 520-527
- ISSN
- 0004-945X (ISSN-L)
- 0818-9641
- 1440-1711
- OpenAlex
- W2028312550
- Cited by
- 38
- References
- 5
- FWCI
- 1.97
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.